METHYLOMIC PROJECT | Second Meeting and Consortium General Assembly (CGA)

December 14, 2023

The second Network Meeting and Consortium General Assembly (CGA) for the Methylomic Project took place in Amsterdam yesterday. Asphalion is the regulatory partner of the project and our expert Diego Sanoja carried out a presentation of the status of the project around the regulatory challenges, which include:

  • Update on the in vitro Diagnostic Assay and Software development.
  • Regulatory Strategy for Companion Diagnostic (CDx) Device.
  • Support on Performance Study framework and pathway for authorization.

 

Partners from different Work Packages presented their advances so far, and conclusions for future actions were agreed upon by the whole METHYLOMIC Consortium. Among these activities we find: clinical study design, communication and dissemination of the project, scientific publications and activities, product development and product validation, as well as next assemblies.

The project METHYLOMIC is aiming to enhance the effectiveness of medication in chronic immune-mediate diseases such as Crohn’s Disease (CD), Rheumatoid Arthritis (RA), and Psoriasis (PsO). It aims specifically for the so-called biologicals, which are antibodies designed to target an inflammatory protein to reduce the inflammation.

For further information about the project please check: https://methylomic.eu/

Thank you very much to the Amsterdam Medical Center (AMC) for hosting such a great and productive meeting!

If you need information or have requests regarding your HORIZON projects, you contact us at: [email protected]

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON EUROPE | NABIHEAL progress meeting

Two years into the NABIHEAL project, Asphalion experts Marta Rayo Lunar and Sergio Veiga attended the consortium meeting in Zagreb, hosted by IMI, to review

HORIZON EUROPE PROJECT | KeratOPrinter Kick-Off Meeting

Corneal blindness affects over 11.7 million people worldwide, yet only 1 in 70 patients receive a corneal transplant due to a severe donor shortage. The KeratOPrinter project aims to address this gap by developing a groundbreaking 4D bioprinting suite capable of producing fully functional, biocompatible human corneas. Combining expertise from world-class partners, the project focuses on scalable cell sources, advanced bioinks, high-precision bioprinting, clinical handling solutions, regulatory compliance, and a strong collaborative network. By 2035, KeratOPrinter seeks to revolutionize corneal transplantation and restore vision for millions.

ARDAT PROJECT

A new year, new classes, and a deep dive into advanced therapies, including discussions on the ARDAT project, as part of the University of Sheffield’s

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting